Recursion Pharmaceuticals, Inc. (RXRX) Net margin 2019–2025
Recursion Pharmaceuticals, Inc. (RXRX) net profit margin by fiscal year — reported net income divided by reported revenue.
-863.4%FY2025 · since FY2019: -2668.3% → -863.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -863.4% | -75.3 pp |
| FY2024 | -788.0% | -52.0 pp |
| FY2023 | -736.0% | -134.9 pp |
| FY2022 | -601.0% | +1231.1 pp |
| FY2021 | -1832.2% | +363.8 pp |
| FY2020 | -2196.0% | +472.3 pp |
| FY2019 | -2668.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Total liabilitiesRXRX Shareholders’ equityRXRX overview →